Characterization of host immune responses in Ebola virus infections

Ebola causes highly lethal hemorrhagic fever in humans with no licensed countermeasures. Its virulence can be attributed to several immunoevasion mechanisms: an early inhibition of innate immunity started by the downregulation of type I interferon, epitope masking and subversion of the adaptive humoural immunity by secreting a truncated form of the viral glycoprotein. Deficiencies in specific and non-specific antiviral responses result in unrestricted viral replication and dissemination in the host, causing death typically within 10 days after the appearance of symptoms. This review summarizes the host immune response to Ebola infection, and highlights the short- and long-term immune responses crucial for protection, which holds implications for the design of future vaccines and therapeutics.

[1]  M. K. Hart,et al.  Protection from Ebola Virus Mediated by Cytotoxic T Lymphocytes Specific for the Viral Nucleoprotein , 2001, Journal of Virology.

[2]  R. Ahmed,et al.  Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection. , 2003, Virology.

[3]  V. Volchkov,et al.  Ebola Virus VP24 Binds Karyopherin α1 and Blocks STAT1 Nuclear Accumulation , 2006, Journal of Virology.

[4]  Sinroku Otatume,et al.  Ebola haemorrhagic fever in Zaire , 1996 .

[5]  P. Rollin,et al.  Cytokine and chemokine expression in humans infected with Sudan Ebola virus. , 2007, The Journal of infectious diseases.

[6]  N. Wauquier,et al.  Risk factors for Zaire ebolavirus--specific IgG in rural Gabonese populations. , 2011, The Journal of infectious diseases.

[7]  X. Qiu,et al.  Immune Parameters Correlate with Protection Against Ebola Virus Infection in Rodents and Nonhuman Primates , 2012, Science Translational Medicine.

[8]  P. Bates,et al.  Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein , 2009, Proceedings of the National Academy of Sciences.

[9]  D. Swenson,et al.  Induction of Humoral and CD8+ T Cell Responses Are Required for Protection against Lethal Ebola Virus Infection1 , 2005, The Journal of Immunology.

[10]  P. Debré,et al.  Early immune responses accompanying human asymptomatic Ebola infections , 2001, Clinical and experimental immunology.

[11]  H. Klenk,et al.  The Ebola Virus VP35 Protein Inhibits Activation of Interferon Regulatory Factor 3 , 2003, Journal of Virology.

[12]  A. Rowe,et al.  Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. , 1999, The Journal of infectious diseases.

[13]  J. Wilson,et al.  Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. , 2001, Virology.

[14]  M. Bray,et al.  Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. , 2005, The international journal of biochemistry & cell biology.

[15]  V. Volchkov,et al.  Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. , 2006, Journal of virology.

[16]  W. Kalina,et al.  Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. , 2007, The Journal of infectious diseases.

[17]  I. Weissman,et al.  In vivo natural killer cell activities revealed by natural killer cell-deficient mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Katze,et al.  Global Suppression of the Host Antiviral Response by Ebola- and Marburgviruses: Increased Antagonism of the Type I Interferon Response Is Associated with Enhanced Virulence , 2006, Journal of Virology.

[19]  P. Debré,et al.  Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients , 1999, Nature Medicine.

[20]  H. Young,et al.  Role of Natural Killer Cells in Innate Protection against Lethal Ebola Virus Infection , 2004, The Journal of experimental medicine.

[21]  J. Kuhn,et al.  Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain , 2012, Virology Journal.

[22]  B. Murphy,et al.  Successful Topical Respiratory Tract Immunization of Primates against Ebola Virus , 2007, Journal of Virology.

[23]  T. Decker,et al.  Type I interferons as mediators of immune adjuvants for T- and B cell-dependent acquired immunity. , 2009, Vaccine.

[24]  Erica Ollmann Saphire,et al.  Ebola Virus VP35 Protein Binds Double-Stranded RNA and Inhibits Alpha/Beta Interferon Production Induced by RIG-I Signaling , 2006, Journal of Virology.

[25]  P. Jahrling,et al.  Apoptosis Induced In Vitro and In Vivo During Infection by Ebola and Marburg Viruses , 2000, Laboratory Investigation.

[26]  Virgil L. Woods,et al.  Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression , 2009, Proceedings of the National Academy of Sciences.

[27]  P. Debré,et al.  Human asymptomatic Ebola infection and strong inflammatory response , 2000, The Lancet.

[28]  B. Pulendran,et al.  Cutting Edge: Impairment of Dendritic Cells and Adaptive Immunity by Ebola and Lassa Viruses1 , 2003, The Journal of Immunology.

[29]  J. Dye,et al.  Protective Cytotoxic T-Cell Responses Induced by Venezuelan Equine Encephalitis Virus Replicons Expressing Ebola Virus Proteins , 2005, Journal of Virology.

[30]  X. Qiu,et al.  mAbs and Ad-Vectored IFN-α Therapy Rescue Ebola-Infected Nonhuman Primates When Administered After the Detection of Viremia and Symptoms , 2013, Science Translational Medicine.

[31]  B. Prabhakar,et al.  The VP35 protein of Ebola virus impairs dendritic cell maturation induced by virus and lipopolysaccharide. , 2010, The Journal of general virology.

[32]  P. Rollin,et al.  Ebola Reston virus infection of pigs: clinical significance and transmission potential. , 2011, The Journal of infectious diseases.

[33]  J Bertolli,et al.  Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidémies à Kikwit. , 1999, The Journal of infectious diseases.

[34]  X. Qiu,et al.  Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb , 2013, Scientific Reports.

[35]  P. Jahrling,et al.  ELISA for the detection of antibodies to Ebola viruses. , 1999, The Journal of infectious diseases.

[36]  G. Ruthel,et al.  Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. , 2003, The Journal of infectious diseases.

[37]  S. Fisher-Hoch,et al.  Apoptosis in fatal Ebola infection. Does the virus toll the bell for immune system? , 2000, Apoptosis.

[38]  S. Pöhlmann,et al.  How Ebola Virus Counters the Interferon System , 2012, Zoonoses and public health.

[39]  M. Bray,et al.  3-deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice. , 2002, Antiviral research.

[40]  E. Nabel,et al.  Immunization for Ebola virus infection , 1998, Nature Medicine.

[41]  M. Georges-Courbot,et al.  Inflammatory responses in Ebola virus‐infected patients , 2002, Clinical and experimental immunology.

[42]  Joshua C. Johnson,et al.  Demonstration of Cross-Protective Vaccine Immunity against an Emerging Pathogenic Ebolavirus Species , 2010, PLoS pathogens.

[43]  A. MacNeil,et al.  Serology and cytokine profiles in patients infected with the newly discovered Bundibugyo ebolavirus. , 2012, Virology.

[44]  R. Ahmed,et al.  Persistent Infection with Ebola Virus under Conditions of Partial Immunity , 2004, Journal of Virology.

[45]  P. Bates,et al.  Steric Shielding of Surface Epitopes and Impaired Immune Recognition Induced by the Ebola Virus Glycoprotein , 2010, PLoS pathogens.

[46]  R. Compans,et al.  Antigenic Subversion: A Novel Mechanism of Host Immune Evasion by Ebola Virus , 2012, PLoS pathogens.

[47]  A. Sanchez,et al.  Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. , 1999, The Journal of infectious diseases.

[48]  C. Goldsmith,et al.  Pathologic features of filovirus infections in humans. , 1999, Current topics in microbiology and immunology.

[49]  H. Feldmann,et al.  Recombinant Vesicular Stomatitis Virus Vector Mediates Postexposure Protection against Sudan Ebola Hemorrhagic Fever in Nonhuman Primates , 2008, Journal of Virology.

[50]  G. Kobinger,et al.  Transmission of Ebola virus from pigs to non-human primates , 2012, Scientific Reports.

[51]  G. Landucci,et al.  Role of CD8+ cells in controlling replication of nonpathogenic Simian Immunodeficiency Virus SIVmac1A11 , 2006, Virology Journal.

[52]  Heinz Feldmann,et al.  Disease modeling for Ebola and Marburg viruses , 2009, Disease Models & Mechanisms.

[53]  Steven B. Bradfute,et al.  Ebola Zaire Virus Blocks Type I Interferon Production by Exploiting the Host SUMO Modification Machinery , 2009, PLoS pathogens.

[54]  M. Katze,et al.  Antibodies are necessary for rVSV/ZEBOV-GP–mediated protection against lethal Ebola virus challenge in nonhuman primates , 2013, Proceedings of the National Academy of Sciences.

[55]  A. Takada,et al.  Protective Efficacy of Neutralizing Monoclonal Antibodies in a Nonhuman Primate Model of Ebola Hemorrhagic Fever , 2012, PloS one.

[56]  G. Trinchieri,et al.  Type I interferon: friend or foe? , 2010, The Journal of experimental medicine.

[57]  H. Ebihara,et al.  The Ebola Virus Glycoprotein Contributes to but Is Not Sufficient for Virulence In Vivo , 2012, PLoS pathogens.

[58]  H. Artsob,et al.  Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. , 2011, The Journal of infectious diseases.

[59]  J. Strong,et al.  Enhanced Protection against Ebola Virus Mediated by an Improved Adenovirus-Based Vaccine , 2009, PloS one.

[60]  S. Hazar,et al.  Filoviridae: Marburg and Ebola viruses. , 2000 .

[61]  N. Wauquier,et al.  Human Fatal Zaire Ebola Virus Infection Is Associated with an Aberrant Innate Immunity and with Massive Lymphocyte Apoptosis , 2010, PLoS neglected tropical diseases.

[62]  E. Mühlberger,et al.  Ebola Virus VP35 Antagonizes PKR Activity through Its C-Terminal Interferon Inhibitory Domain , 2009, Journal of Virology.

[63]  N. Sullivan,et al.  Immunopathology of highly virulent pathogens: insights from Ebola virus , 2007, Nature Immunology.

[64]  Heinz Feldmann,et al.  A New Ebola Virus Nonstructural Glycoprotein Expressed through RNA Editing , 2011, Journal of Virology.

[65]  K. Propert,et al.  Immune responses to adenovirus and adeno-associated virus in humans , 1999, Gene Therapy.

[66]  M. Bray,et al.  Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. , 2001, Journal of comparative pathology.

[67]  P. Jahrling,et al.  Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. , 2003, The Journal of infectious diseases.

[68]  Z. Otwinowski,et al.  Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35 , 2010, Nature Structural &Molecular Biology.

[69]  R. Ahmed,et al.  Passive Transfer of Antibodies Protects Immunocompetent and Immunodeficient Mice against Lethal Ebola Virus Infection without Complete Inhibition of Viral Replication , 2001, Journal of Virology.

[70]  Majidat A. Muhammad,et al.  Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu). , 2013, The Journal of infectious diseases.

[71]  L. Fernando,et al.  Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. , 2007, The Journal of infectious diseases.

[72]  N. Wauquier,et al.  Immunoglobulin G in Ebola Outbreak Survivors, Gabon , 2009, Emerging infectious diseases.

[73]  C. Basler,et al.  Ebola Virus VP24 Proteins Inhibit the Interaction of NPI-1 Subfamily Karyopherin α Proteins with Activated STAT1 , 2007, Journal of Virology.

[74]  A. Takada,et al.  Differential potential for envelope glycoprotein-mediated steric shielding of host cell surface proteins among filoviruses. , 2013, Virology.

[75]  N. Wauquier,et al.  High Prevalence of Both Humoral and Cellular Immunity to Zaire ebolavirus among Rural Populations in Gabon , 2010, PloS one.

[76]  P. Jahrling,et al.  DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. , 1998, Virology.

[77]  L. Hensley,et al.  Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions , 2004, Expert Reviews in Molecular Medicine.

[78]  J. Gonzalez,et al.  Cutaneous manifestations of filovirus infections , 2012, International journal of dermatology.

[79]  Jeffrey E. Lee,et al.  The Secret Life of Viral Entry Glycoproteins: Moonlighting in Immune Evasion , 2013, PLoS pathogens.

[80]  M. Bray.  The role of the Type I interferon response in the resistance of mice to filovirus infection. , 2001, The Journal of general virology.

[81]  P. Jahrling,et al.  Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. , 2002, Immunology letters.

[82]  Lisa Hensley,et al.  Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques , 2012, Proceedings of the National Academy of Sciences.

[83]  J. Dye,et al.  Persistent immune responses after Ebola virus infection. , 2013, The New England journal of medicine.

[84]  Heinz Feldmann,et al.  Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses , 2005, Nature Medicine.

[85]  Mario Roederer,et al.  CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates , 2011, Nature Medicine.

[86]  M. Lackemeyer,et al.  Aerosol exposure to Zaire ebolavirus in three nonhuman primate species: differences in disease course and clinical pathology. , 2011, Microbes and infection.

[87]  Majidat A. Muhammad,et al.  Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease , 2012, Proceedings of the National Academy of Sciences.

[88]  H. Feldmann,et al.  Ebola haemorrhagic fever , 2011, The Lancet.

[89]  P. Jahrling,et al.  Induction of Immune Responses in Mice and Monkeys to Ebola Virus after Immunization with Liposome-Encapsulated Irradiated Ebola Virus: Protection in Mice Requires CD4+ T Cells , 2002, Journal of Virology.

[90]  G. Kobinger,et al.  Replication, pathogenicity, shedding, and transmission of Zaire ebolavirus in pigs. , 2011, The Journal of infectious diseases.

[91]  X. Qiu,et al.  Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal Antibodies , 2012, Science Translational Medicine.

[92]  Joshua C. Johnson,et al.  Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. , 2013, The Journal of infectious diseases.

[93]  R. Ribeiro,et al.  Experimental depletion of CD8+ cells in acutely SIVagm-Infected African Green Monkeys results in increased viral replication , 2010, Retrovirology.